FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a new compound of formula (I) or its pharmaceutically acceptable salt possessing the properties of blood coagulation inhibitor. In the compound of formula (I) , R1 represents 1) phenyl optionally substituted by one to three C1-C6alkyl groups, 2) C1-C6alkoxy or 3) C2-C6alkenyloxy； R2 represents a hydrogen atom, C1-C6alkylcarbonyl or pyridylcarbonyl； each of R3 and R4 independently represents a hydrogen atom or C1-C6alkyl； A represents a single bond, oxygen atom, or a group presented by formula (II) , wherein each of Ra and Rb independently represents a hydrogen atom or C1-C6alkyl, whereas *1 and *2 mean a binding to carbonyl and R5, respectively, in formula (I), or a group presented by formula (III) , wherein each of Rc, Rd, Re and Rf independently represents a hydrogen atom or C1-C6alkyl, whereas *1 and *2 are characterised by the same values described above； and R5 represents C1-C6alkyl or C3-C8cycloalkyl, whereas C1-C6alkyl or C3-C8cycloalkyl in R5 is independently substituted by one to three identical or different substitutes specified in a group of substitutes consisting of a halogen atom, C1-C6akyl and C1-C6alkoxy.EFFECT: compounds can find application in the diseases caused by thrombus formation, such as thrombosis, deep-vein thrombosis, pulmonary embolism, cerebral infarction, myocardial infarction, acute coronary syndrome, vascular restenosis, disseminated intravascular coagulation, or malignant tumour.16 cl, 6 dwg, 5 tbl, 68 exИзобретение относится к новому соединению формулы (I) или его фармацевтически приемлемой соли, обладающим свойствами ингибитора коагуляции крови. Соединения могут найти применение при заболеваниях, вызванных образованием тромба, таких как тромбоз, тромбоз глубокой вены, легочная эмболия, церебральный инфаркт, инфаркт миокарда, острый коронарный синдром, сосудистый рестеноз, синдром диссеминированной внутрисосудистой коагуляции или злокачественная опухоль. В соединении фор
